#1leading
Shared MYD88/NF-κB mechanism drives both autoinflammation and B-cell clonality
48 studies·pathogenesis
55
evidence
Schnitzler Syndrome
Also known asSchnitzler's SyndromeSchS
Rare acquired autoinflammatory disorder characterised by chronic urticarial rash with monoclonal IgM gammopathy and systemic inflammation. First described in 1972 by Liliane Schnitzler, the syndrome involves dysregulated IL-1β signalling driving fever, bone pain, arthralgia, and elevated inflammatory markers.
Data sourced from 79 published studies with evidence grading (A–D). Last reviewed . Not medical advice.
Pathophysiology◐Partially understood
Treatment✓Effective options available
Genetic basis○Under investigation
Publications per year
1993: 1 study
932000: 1 study
2001: 1 study
2003: 1 study
2005: 1 study
2006: 2 studies
2007: 3 studies
2008: 1 study
2009: 1 study
2010: 2 studies
2011: 1 study
2012: 3 studies
2013: 4 studies
2014: 4 studies
2015: 4 studies
2016: 1 study
2017: 2 studies
2018: 5 studies
2019: 6 studies
2021: 4 studies
2022: 2 studies
2023: 1 study
2024: 7 studies
2025: 18 studies
2026: 3 studies
26Epidemiology
- Total cases
- 748
- Mean onset
- 53 years
- Onset range
- 13–71 years
- Sex ratio (M:F)
- 1.76:1
- Diagnostic delay
- ~5 years
- Discovered
- 1972 (Liliane Schnitzler)
- Prevalence
- <1/1,000,000
- Classification
- Autoinflammatory, Hematologic
Cardinal Features
8 key symptoms and signs
| Feature | Frequency | Category | Sources |
|---|---|---|---|
Chronic urticarial rash Non-pruritic or mildly pruritic wheals, often worse in evening. Individual lesions last <24 hours. Neutrophilic dermal infiltrate on biopsy. | 100% | dermatologic | |
Monoclonal IgM gammopathy Obligate diagnostic criterion. IgM-kappa in ~94% of cases. M-spike often low (median 0.6 g/dL). SPEP alone may miss it in 51% — immunofixation required. | 100% | laboratory | |
Recurrent fever Intermittent fever >38°C, often in evening. Resolves within hours of anakinra. | 85% | systemic | |
Bone pain Predominantly distal femora and proximal tibiae ('hot knees'). Osteosclerotic lesions on imaging in 64%. | 70% | musculoskeletal | |
Arthralgia Joint pain without destructive arthropathy. Large joints most commonly affected. | 75% | musculoskeletal | |
Fatigue Often severe and debilitating. Correlates with inflammatory marker levels. | 80% | systemic | |
Elevated CRP Consistently elevated C-reactive protein reflecting systemic inflammation. Normalizes rapidly with IL-1 blockade. | 95% | laboratory | |
Elevated ESR Erythrocyte sedimentation rate >20 mm/h. Minor criterion in Lipsker criteria. | 90% | laboratory |
Hypothesis Tracker
Competing explanations ranked by evidence weight
#2competing
Independent parallel processes: inflammasome dysregulation and MGUS are separate consequences of an upstream event
30 studies·pathogenesis
35
evidence
#3competing
IL-1 blockade may prevent lymphoproliferative transformation to Waldenström's
12 studies·treatment
30
evidence
#4emerging
Schnitzler syndrome is a spectrum, not a single disease
15 studies·pathogenesis
30
evidence
#5weakening
Monoclonal IgM directly triggers inflammasome activation (autoantibody model)
22 studies·pathogenesis
25
evidence
#6emerging
NLRP3 somatic mosaicism is the primary driver in a subset of patients
8 studies·genetics
20
evidence
#7emerging
Pyrin-inflammasome dysfunction (MEFV variants) contributes to pathogenesis
4 studies·genetics
15
evidence
Open Questions
What is the relationship between the monoclonal gammopathy and the autoinflammation?
Three competing hypotheses exist. MYD88 L265P is the strongest candidate for a shared mechanism but is absent in ~70% of patients.
What triggers the initial inflammasome dysregulation?
No consistent genetic mutation identified. Environmental triggers? Stochastic cellular events? Epigenetic dysregulation?
Does IL-1 blockade prevent lymphoproliferative transformation?
Suggestive data from the French cohort but IL-1 therapy does not alter monoclonal component levels. Needs long-term prospective studies.
Can ibrutinib address both the inflammatory and gammopathy components simultaneously?
Only agent shown to reduce monoclonal protein AND control symptoms. Very limited data. Needs prospective trials.
Is Schnitzler syndrome truly a single disease or a spectrum?
Growing recognition of IgG variants, Schnitzler-like syndromes without gammopathy, and molecular subtypes.
What is the role of newly identified genes (MEFV, F2)?
MEFV variants found in some patients (2024-2025). MEFV encodes pyrin (inflammasome inhibitor). Significance uncertain.
Recent Updates
Novel MEFV/F2 gene variants in 748th Schnitzler case
Case report from Hungary identified novel MEFV gene variant c.2084A>G and F2 gene variant. Strengthens pyrin-inflammasome hypothesis.
Bortezomib (proteasome inhibitor) case report published
Novel use of bortezomib in a patient without detectable serum IL-1β and absent MYD88 L265P.
First Schnitzler syndrome cases reported from Iran
Aminianfar et al. (2025) reported the first cases from Iran, highlighting challenges without access to IL-1 inhibitors.
First IgA λ-type Schnitzler syndrome case reported
Hiroyasu et al. (2026) reported the first IgA lambda-type case with edema and numbness, expanding the immunoglobulin spectrum beyond IgM and IgG.
Systematic review questions obligate gammopathy criterion
Zhu et al. (2025) reviewed 18 patients with SS lacking monoclonal gammopathy. 77.8% had absent gammopathy; anakinra achieved 92.9% complete response. Suggests gammopathy may not be obligate for diagnosis.
AIDA Network real-world IL-1 inhibitor data: 60-month retention 64.7%
Calabrese et al. (2025) reported long-term real-world effectiveness of anakinra and canakinumab in 28 SchS patients (37 treatment lines) from the international AIDA Network registry. Complete response rates were 73.1% (anakinra) and 66.8% (canakinumab). Drug retention at 60 months was 64.7%. Elevated IgG M-protein and lymphadenopathy independently predicted treatment discontinuation.
Neutrophils identified as predominant IL-1β source in SchS skin
Kambe et al. (2025) demonstrated that neutrophils are the main IL-1β-expressing cells in Schnitzler syndrome lesional skin and blood, using data from the SCan canakinumab study in Japanese patients. This provides mechanistic insight into why IL-1 blockade is so effective and positions neutrophil-targeted approaches as a research avenue.
Low-level NLRP3 mosaicism extends Schnitzler phenotypic spectrum
Daskalopoulou et al. (2025) detected low-level somatic NLRP3 mosaicism in four patients with chronic urticarial lesions including Schnitzler syndrome cases, extending the phenotypic spectrum of NLRP3-related disorders. Findings support considering NLRP3 inhibitor therapy in select Schnitzler-spectrum patients.
Weekly research monitor: 7 new sources added (2025-2026)
Automated weekly search (2026-03-27) found 7 new publications not previously indexed. New entries include: AIDA Network real-world IL-1 data (K2), VEXAS vs Schnitzler differential markers (K3), neutrophil IL-1β source study (K4), NLRP3 mosaicism in urticarial lesions (K5), canakinumab in anakinra-refractory SchS (K6), paraprotein-negative Schnitzler-like syndrome update (K7), and Schnitzler+RA case (K8). No new clinical trials or preprints found. Baseline quality score: 79.7/100.
Weekly research monitor: 4 new sources added (2025-2026)
Automated weekly search (2026-03-29) found 4 new publications not previously indexed. New entries include: comprehensive review of chronic urticaria and autoinflammatory syndromes highlighting IL-1beta's central role (L1, Yacoub et al. 2025), Swiss clinical review emphasising Strasbourg criteria and underdiagnosis risk (L2, Leggeri et al. 2025), Polish case report confirming anakinra effectiveness in real-world practice (L3, Moos et al. 2025), and expert commentary supporting broader diagnostic criteria for gammopathy-negative Schnitzler syndrome (L4, Fagan et al. 2025). No new clinical trials found (existing 10 trials unchanged). No Schnitzler syndrome preprints found on bioRxiv/medRxiv.